Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Sandisk Announces Additional $750 Mln Stock Repurchase Plan - Quick Facts

RELATED NEWS
Trade SNDK now with 

SanDisk Corp. (SNDK: Quote) announced that its Board of Directors has authorized an additional $750 million for common stock repurchases, increasing the total amount authorized for stock repurchases under the current program to $1.25 billion.

The company said the current repurchase program was established on Oct. 27, 2011 and will expire on Oct. 26, 2016.

To date under this program, the company has used about $234 million for stock repurchases and approximately $1.016 billion remains available.

SanDisk said that under the expanded program, stock repurchases may be made from time to time and the actual amount expended will depend on a variety of factors including market conditions, regulatory and legal requirements, corporate cash generation and other factors.

Click here to receive FREE breaking news email alerts for Sandisk Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks have moved mostly lower in early trading on Monday after opening the session near the unchanged line. The major averages have slid firmly into negative territory, with the S&P 500 pulling back further off last Thursday's record closing high. President Barack Obama is meeting with presidents from Central American nations on Friday as the U.S. struggles to deal with a surge of unaccompanied children across the southern border. Despite calls from some leading conservatives, the results of a new CNN/ORC International poll released Friday showed that a vast majority of Americans do not believe that President Barack Obama should be impeached and removed from office.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.